PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
78.38%
Growth of 78.38% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
8.67%
Cost growth of 8.67% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
140.18%
Growth of 140.18% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
-39.19%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-40.71%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
74.54%
Marketing expense change of 74.54% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-69.36%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-3.37%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is -3.65%. Seth Klarman would investigate advantages.
28.01%
Total costs growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-24.63%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
2.30%
D&A growth near Drug Manufacturers - Specialty & Generic median of 2.30%. Charlie Munger would verify industry norms.
20.26%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.44%. Joel Greenblatt would investigate advantages.
55.30%
Margin change of 55.30% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
12.00%
Operating income growth near Drug Manufacturers - Specialty & Generic median of 11.61%. Charlie Munger would verify industry dynamics.
50.67%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.55%. Joel Greenblatt would investigate advantages.
19.52%
Other expenses growth near Drug Manufacturers - Specialty & Generic median of 19.52%. Charlie Munger would verify if industry norms make sense.
14.27%
Pre-tax income growth near Drug Manufacturers - Specialty & Generic median of 14.27%. Charlie Munger would verify industry dynamics.
51.94%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.10%. Joel Greenblatt would investigate advantages.
100.00%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.72%. Jim Chanos would check for issues.
14.27%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.28%. Joel Greenblatt would investigate advantages.
51.94%
Margin change of 51.94% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
13.68%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.28%. Joel Greenblatt would investigate advantages.
13.68%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.52%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.